Noxxon starts study in diabetic nephropathy

Tuesday 19 June 2012

Noxxon Pharma AG has started a Phase 2a trial of an oligonucleotide-based drug for patients with diabetic nephropathy. The drug, NOX-E36, aims to bind and neutralise MCP-1, a protein that is involved in inflammation.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany